Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
  • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/08—Antiepileptics; Anticonvulsants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/06—Antiarrhythmics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/08—Vasodilators for multiple indications
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
  • C07D457/02—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with hydrocarbon or substituted hydrocarbon radicals, attached in position 8
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
  • C07D519/02—Ergot alkaloids of the cyclic peptide type

Definitions

• R II alkyl (C 1 -C 6 ), phenyl
• x Y CH 2 --CH ⁇ , CH ⁇ C ⁇ .
• aprotic solvents such as methylene chloride, chloroform, dichloroethane, tetrahydrofuran, ethylene glycol dimethylether, etc.
• reaction products can be separated and purified with usual methods such as for example crystallization, column chromatographic separation on SiO 2 , Al 2 O 3 , etc. Separation, purification and yield are greatly simplified and improved when the reaction products are treated with Raney Ni in alcoholic solvents such as methanol, ethanol, in a temperature range from 25° C. to 150° C. to eliminate all the labile secondary products of polysubstitution.
• alcoholic solvents such as methanol, ethanol
• the compounds of general formula I are generally solid, crystalline and provide pharmaceutically acceptable salts with inorganic acids such as hydrochloric, hydrobromic, sulphuric, phosphoric acid, or organic acids, such as maleic, tartaric, citric, methansulphonic, etc.
• inorganic acids such as hydrochloric, hydrobromic, sulphuric, phosphoric acid, or organic acids, such as maleic, tartaric, citric, methansulphonic, etc.
• the new compounds can be used as drugs as such or in the form of suitable salts with pharmaceutically acceptable acids, in doses of 0.1-10 mg.
• the pharmaceutical dosage form can be tablets, sugar-coated tablets, drops, vials, suppositories.
• the solid forms for oral use can be formulated by mixing the active ingredient with various vehicles and diluents, such as lactose, mannitol, starch, cellulose and derivatives thereof, and lubricants such as magnesium or calcium stearate.
• various vehicles and diluents such as lactose, mannitol, starch, cellulose and derivatives thereof, and lubricants such as magnesium or calcium stearate.
• the mixtures so obtained as treated to provide tablets or cores and these latter can be subsequently coated with sugar containing gum arabic, talc and a suitable lake or dye.
• the said pharmaceutical product can be formulated as hard or soft gelatin capsules.
• the active ingredient is preferably dissolved or suspended in a suitable liquid such as polyoxyethyleneglycol in the presence of a stabilizer such as sodium metabisulphite or ascorbic acid.
• a suitable liquid such as polyoxyethyleneglycol
• a stabilizer such as sodium metabisulphite or ascorbic acid.
• the active ingredient can be formulated for example in gelatin capsules for rectal use or with a vehicle for suppositories, for instance natural triglycerides such as cocoa butter.
• the solution for parenteral use or the drops for oral use can be prepared by dissolving the active ingredient as such or in the form of a salt in a suitable dissolving and stabilizing agent comprising for example only sterile water or water containing 5-20% of ethanol, glycerol, propyleneglycol.
• a suitable dissolving and stabilizing agent comprising for example only sterile water or water containing 5-20% of ethanol, glycerol, propyleneglycol.
• the compounds from 7 to 17 are prepared similarly.
• D-6-methyl-z-phenylthio-8beta perhydroazepinil carbonyloxymethyl)-ergoline (compound No. 20) is similarly prepared.
• the compounds claimed in the present invention show interesting pharmacological properties, evidenced by means of classical tests on laboratory animals at extremely low doses.
• the new compounds show alpha-blocking and vasodilator, anti-hypertensive, anti-serotonic both peripheral and central- and anti-asthmatic, anti-depressive and, in two cases, analgesic properties.
• compounds 11 and 9 have a broad spectrum of pharmacologycal properties, shown in the following table, compared to known substances used as comparison.
• the two new compounds 9 and 11 possess high adrenolytic and anti-serotininic activity and for such compounds a pharmaceutical use as psychopharmacologic drugs and vasedilators is foreseen.
• compound No. 10 shows itself to be active both as adrenolytic (EC 50 3.7 ng/ml and ED 50 20 ⁇ g/kg) and as spasmolytic (EC 50 2 ⁇ g/ml) and as antiasthmatic.
• This Table shows how some of the compounds listed are exceptionally active, up to 1000-2500 times the standard, and, in the absence of other important pharmacological activities except for a potent analgesic activity of compounds Nos. 12 and 14, the ED 100 which is 2.5 mg/kg/sc and 5 mg/kg/sc respectively, versus the ED 100 of D-propoxyphene, which is 10 mg/kg/sc, a pharmaceutical use is foreseen for said compounds, as anti-depressive drugs.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Pain & Pain Management (AREA)
• Psychiatry (AREA)
• Pulmonology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=4337542

Family Applications (1)

Country Status (7)

Cited By (5)

Families Citing this family (2)

Citations (4)

Family Cites Families (4)

• 1978
  • 1978-05-26 IT IT23911/78A patent/IT1192260B/it active
  • 1978-06-20 US US05/917,335 patent/US4197299A/en not_active Expired - Lifetime
  • 1978-06-30 JP JP7879378A patent/JPS5414999A/ja active Granted
  • 1978-07-05 GB GB7828932A patent/GB2000772B/en not_active Expired
  • 1978-07-05 BE BE189095A patent/BE868768A/xx unknown
  • 1978-07-05 DE DE19782829471 patent/DE2829471A1/de active Granted
  • 1978-07-05 FR FR7820054A patent/FR2396758A1/fr active Granted

Patent Citations (4)

Non-Patent Citations (4)

Also Published As

Similar Documents